ArticleJournal of thoracic disease2025
Efficacy and safety of datopotamab deruxtecan in advanced/metastatic non-small cell lung cancer patients: a systematic review and single-arm meta-analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolution and recent advances in antibody-drug conjugate therapy for lung cancer: a comprehensive systematic review based on the Trialtrove database (inception to July 1, 2025).Frontiers in oncology · 2026Pooled it
- Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges.Pharmaceutics · 2026Review
- Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer.Future oncology (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Datopotamab deruxtecan (dato-DXd), an antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2), has shown promising results in advanced/metastatic (a/m) non-small cell lung cancer (NSCLC). This systematic review and meta-analysis evaluated the efficacy and safety of dato-DXd in this population. Methods: A systematic search from inception until July 14, 2024 was performed on PubMed, Embase, Cochrane, the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) databases for studies examining dato-DXd in patients with a/m NSCLC. Outcomes were progression-free survival (PFS) and overall survival (OS), objective response rate (ORR), disease control rate (DCR), and incidence of adverse events (AEs). Random-effect models were used for analysis. Results: Seven clinical trials involving 914 a/m NSCLC patients treated with dato-DXd were included. Most patients received dato-DXd as monotherapy (6 mg/kg Q3W). Overall, 35% [95% confidence interval (CI): 27-43%] achieved an ORR, and 78% (95% CI: 75-81%) achieved a DCR. Non-squamous histology showed numerically higher ORR (28% Conclusions: Dato-DXd demonstrated notable efficacy in heavily pretreated a/m NSCLC patients, with a median PFS and OS of 5.4 and 11.9 months, respectively. The rate of AE was substantial, including treatment discontinuation in nearly one-quarter of patients. Ongoing studies on the activity and safety profile of dato-DXd in a/m NSCLC are awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.